Provided by Tiger Fintech (Singapore) Pte. Ltd.

ASCLETIS-B

12.970
+1.0708.99%
Volume:4.15M
Turnover:51.96M
Market Cap:12.87B
PE:-39.41
High:13.000
Open:11.920
Low:11.890
Close:11.900
52wk High:18.750
52wk Low:1.480
Shares:992.00M
HK Float Shares:992.00M
Volume Ratio:4.81
T/O Rate:0.42%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.329
ROE:-12.77%
ROA:-12.32%
PB:6.29
PE(LYR):-39.41
PS:4968.66

Loading ...

ASCLETIS-B (01672) Repurchases 200,000 Shares for HK$1.93 Million on October 31

Stock News
·
Oct 31

Ascletis Pharma Files HKEX Disclosure on Repurchase of 200,000 Shares at HKD 1,932,670

Reuters
·
Oct 31

HK Movers|Biotech Shares Soar. 3SBIO up 11%; RemeGen up 8%; SKB BIO up 7%; Junshi Bio up 5%; Hengrui Pharma and Innocare up 4%.

Tiger Newspress
·
Oct 31

Hong Kong Stocks Movement | ASCLETIS-B (01672) Rises Over 4% as Subcutaneous Amylin Receptor Agonist ASC36 Enters Clinical Development

Stock News
·
Oct 31

Ascletis Pharma Reports ASC36 Achieves Superior Weight Loss in Preclinical Obesity Studies

Reuters
·
Oct 30

ASCLETIS-B (01672) Selects Best-in-Class Monthly Subcutaneous Amylin Receptor Agonist ASC36 for Clinical Development

Stock News
·
Oct 30

Ascletis Pharma Inc. (1672) Announces Once-Monthly Amylin Receptor Agonist ASC36 for Clinical Development

Bulletin Express
·
Oct 30

HK Stock Buyback Summary | October 29

Stock News
·
Oct 29

Ascletis Pharma (01672) Announces Update on Share Repurchase and Treasury Share Changes

Bulletin Express
·
Oct 28

ASCLETIS-B (01672) Repurchased 100,000 Shares for HK$918,900 on October 28

Stock News
·
Oct 28

Ascletis Pharma Repurchases 100,000 Shares for HKD 918,910 in HKEX Disclosure

Reuters
·
Oct 28

Ascletis Pharma to Present Obesity Drug Study Findings at Georgia Conference

MT Newswires Live
·
Oct 27

Ascletis Pharma (01672) Announces Share Repurchase and Updated Issued Shares

Bulletin Express
·
Oct 27

Ascletis (1672) Announces Multiple Presentations on Obesity Pipeline at ObesityWeek® 2025

Bulletin Express
·
Oct 27

ASCLETIS-B (01672): ASCLETIS to Present Research Findings on ASC30 Oral Tablets, ASC30 Injection, and ASC31 Combined with ASC47 at ObesityWeek® 2025

Stock News
·
Oct 27

Assessing Ascletis Pharma (SEHK:1672) Valuation After Strong Share Price Surge

Simply Wall St.
·
Oct 25

Sagimet Biosciences Reports Denifanstat Meets All Endpoints in Phase 3 Acne Trial

Reuters
·
Oct 24

Ascletis Pharma Inc. (01672) Releases Next Day Disclosure Return on Share Repurchases

Bulletin Express
·
Oct 23

Hong Kong Stock Buyback Statistics | October 23

Stock News
·
Oct 23

Ascletis Pharma Repurchases 100,000 Shares for HKD 926,520 in HKEX Disclosure Return

Reuters
·
Oct 22